» Articles » PMID: 30691934

Novel Inactivating Mutations in the FSH Receptor Cause Premature Ovarian Insufficiency with Resistant Ovary Syndrome

Overview
Publisher Elsevier
Date 2019 Jan 30
PMID 30691934
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Research Question: What is the genetic aetiology of three resistant ovary syndrome (ROS) pedigrees from 13 Chinese Han families with non-syndromic premature ovarian insufficiency (POI).

Design: The proband in each family was subjected to whole-exome sequencing. Bioinformatic and in-vitro functional analyses were performed for the functional characterization of the FSHR mutations.

Results: Four novel mutations, two homozygous mutations (c.419delA, c.1510C>T), and a compound heterozygous mutation (c.44G>A and deletion of exons 1 and 2) of FSHR were identified in the three non-syndromic POI-with-ROS families. Bioinformatic analysis predicted that the three novel point mutations in FSHR are deleterious and associated with POI in the three families, which was confirmed by in-vitro functional analysis, in which FSH-induced adenosine 3',5'-cyclic monophosphate production was abolished for all receptors.

Conclusions: The three novel point mutations in FSHR were all functional inactivating mutations, and were the genetic aetiology of the three non-syndromic POI-with-ROS families. The first FSHR frameshift mutation is reported here, and the first missense mutation in the signal peptide-encoding region of FSHR to be associated with POI. Women affected by ROS should consider undergoing mutation screening for FSHR.

Citing Articles

Resistant ovary syndrome: Two case reports and a literature review of effective controlled ovarian stimulation in IVF.

Zhao S, Zheng W, Gu X, Liang G, Long G Medicine (Baltimore). 2024; 103(18):e37886.

PMID: 38701292 PMC: 11062649. DOI: 10.1097/MD.0000000000037886.


Expanding the phenotypic spectrum of LHCGR signal peptide insertion variant: novel clinical and allelic findings causing Leydig cell hypoplasia type II.

Hassan H, Mazen I, Elaidy A, Kamel A, Eissa N, Essawi M Hormones (Athens). 2024; 23(2):305-312.

PMID: 38526829 PMC: 11219444. DOI: 10.1007/s42000-024-00546-x.


Landscape of pathogenic mutations in premature ovarian insufficiency.

Ke H, Tang S, Guo T, Hou D, Jiao X, Li S Nat Med. 2023; 29(2):483-492.

PMID: 36732629 PMC: 9941050. DOI: 10.1038/s41591-022-02194-3.


Identification and characterization of novel compound heterozygous variants in causing primary ovarian insufficiency with resistant ovary syndrome.

Chen X, Chen L, Wang Y, Shu C, Zhou Y, Wu R Front Endocrinol (Lausanne). 2023; 13:1013894.

PMID: 36704038 PMC: 9871476. DOI: 10.3389/fendo.2022.1013894.


Resistant ovary syndrome: Pathogenesis and management strategies.

Mu Z, Shen S, Lei L Front Med (Lausanne). 2022; 9:1030004.

PMID: 36341241 PMC: 9626816. DOI: 10.3389/fmed.2022.1030004.